Piracetam contains two nitrogen atoms. Aniracetam contains one. That is the first thing to notice when the two structures are set side by side, and it is the detail that most short descriptions of the pair get wrong by calling aniracetam a substituted piracetam.
It is not. The acetamide arm is gone. In its place, the lactam nitrogen carries a 4-methoxybenzoyl substituent, and every downstream difference in polarity, chromatographic behaviour and metabolic fate follows from that one acylation. Understanding what the anisoyl group does is a compact lesson in how a single substitution reorganises a molecule.
Two records, two very different molecules
PubChem lists piracetam as CID 4843: molecular formula C6H10N2O2, molecular weight 142.16 g/mol, IUPAC name 2-(2-oxopyrrolidin-1-yl)acetamide, CAS registry number 7491-74-9. Aniracetam is CID 2196: molecular formula C12H13NO3, molecular weight 219.24 g/mol, IUPAC name 1-(4-methoxybenzoyl)pyrrolidin-2-one, CAS registry number 72432-10-1.
The SMILES strings make the relationship explicit. Piracetam is C1CC(=O)N(C1)CC(=O)N. Aniracetam is COC1=CC=C(C=C1)C(=O)N2CCCC2=O. Both retain the 2-pyrrolidinone ring. Only piracetam retains the primary amide.
The partition coefficient moves by nearly three log units
PubChem’s computed XLogP3 value for piracetam is -1.3. For aniracetam it is 1.6. The anisoyl group therefore shifts the calculated octanol-water partition coefficient by roughly 2.9 log units, which is close to a thousand-fold change in the calculated preference for the organic phase.
Three structural facts produce that shift. An aromatic ring is added, contributing a large non-polar surface. A methoxy substituent adds a weakly polar but largely hydrophobic methyl group. Most importantly, a hydrogen-bond-donating primary amide is removed entirely, taking two N-H donors out of the molecule.
For the analyst the consequence is immediate. Piracetam elutes close to the void volume on a conventional C18 column and resists liquid-liquid extraction into organic solvents. Aniracetam is retained, extracts readily, and absorbs usefully in the ultraviolet thanks to the methoxy-substituted benzoyl chromophore, which the parent scaffold entirely lacks.
An imide is not a lactam
The electronic change is easy to state and easy to underrate. In piracetam, the ring nitrogen is a tertiary amide nitrogen carrying an alkyl chain. In aniracetam, the same nitrogen carries a second carbonyl. A nitrogen flanked by two carbonyl groups is an imide.
Imide nitrogen has to share one lone pair between two competing carbonyls. Neither carbonyl receives full amide resonance stabilisation, so both are more electrophilic than the corresponding carbonyl in a simple lactam, and the C-N bonds are correspondingly more susceptible to nucleophilic attack. The anisoyl group does not merely add bulk and lipophilicity. It converts a robust cyclic amide into a considerably more hydrolytically labile system.
Two hydrolytic outcomes are possible in principle. Attack at the exocyclic carbonyl would release 4-methoxybenzoic acid and regenerate 2-pyrrolidinone. Attack at the endocyclic carbonyl would open the ring to give the corresponding N-acylated 4-aminobutanoic acid. Which of these dominates is a question for experiment rather than for arrow-pushing, and the published bioanalytical literature answers it clearly.
What the plasma assays actually target
Guenzi and Zanetti described two reversed-phase high-performance liquid chromatography (HPLC) methods in the Journal of Chromatography in 1990, measuring aniracetam and N-anisoyl-GABA in plasma. The direct-injection method reached a limit of quantification of 5 ng/ml with 3 per cent inter-assay precision; the liquid-liquid extraction method reached 50 ng/ml with 6 per cent precision. The authors reported applying the procedures to more than a thousand plasma samples from bioavailability studies.
Cai and Wang returned to the same problem with modern instrumentation in the Journal of Chromatography B in 2012. Their liquid chromatography with electrospray tandem mass spectrometry (LC-ESI-MS/MS) method measures 4-p-anisamidobutyric acid, the ring-opened metabolite also written as N-anisoyl-GABA, over a linear range of 0.0485 to 19.4 micrograms per millilitre with a 4.5-minute run time and extraction recovery between 89.1 and 100.7 per cent.
The title of that 2012 paper is the important part. It describes a pharmacokinetic study built around the metabolite, not the parent. The ring-opened product is what there is enough of to measure reliably, which is the analytical signature of extensive presystemic hydrolysis. A separate pharmacokinetic and bioequivalence study by Tian and colleagues, published in Arzneimittelforschung in 2008, addressed the same compound in healthy volunteers.
| Property | Piracetam | Aniracetam |
|---|---|---|
| PubChem CID | 4843 | 2196 |
| Molecular formula | C6H10N2O2 | C12H13NO3 |
| Molecular weight (g/mol) | 142.16 | 219.24 |
| Nitrogen atoms | 2 | 1 |
| Nitrogen environment | tertiary amide plus primary amide | imide |
| XLogP3 (computed) | -1.3 | 1.6 |
| CAS number | 7491-74-9 | 72432-10-1 |
The pharmacology the substitution opened up
Aniracetam earned its place in the electrophysiology literature rather than in the nootropic marketing literature. Ito, Tanabe, Kohda and Sugiyama reported in the Journal of Physiology in 1990 that aniracetam potentiates ionotropic quisqualate responses in Xenopus oocytes injected with rat brain messenger RNA, reversibly and at concentrations above 0.1 mM. The potentiation was accompanied by an increase in conductance without a change in the receptors’ affinity for agonist, and kainate and GABA responses were unaffected.
Isaacson and Nicoll followed in the Proceedings of the National Academy of Sciences in 1991 with the mechanistic reading that stuck: aniracetam reduces glutamate receptor desensitisation and slows the decay of fast excitatory synaptic currents in the hippocampus. That description of positive allosteric modulation, rather than agonism, became the template for a later generation of compounds designed around the same idea.
Two limits are worth stating plainly. These are slice and oocyte experiments, not clinical findings. Malykh and Sadaie noted in their 2010 review in Drugs that aniracetam and oxiracetam are no longer in clinical use, and that the mechanisms of piracetam and most of its derivatives remain unresolved.
Why the anisoyl group matters when handling the standard
A hydrolytically labile imide is a different storage problem from a plain lactam. Aqueous stock solutions of an N-acylated pyrrolidinone should be treated as time-limited and prepared fresh, and any assay that reports the parent compound needs a stability check under its own sample-preparation conditions rather than a citation to somebody else’s.
The ultraviolet chromophore that makes the compound easy to detect is also the part that disappears from the molecule on hydrolysis at the exocyclic carbonyl, which means a detector response can shift without the total mass of related substances changing. Identity and purity should therefore be confirmed against a characterised analytical reference standard supplied with a batch-specific certificate of analysis, and the chromatographic system should be checked for the free acid as a degradation marker. Laboratory ordering conditions for standards of this type are set out in the terms of supply.
Frequently asked questions
What is the anisoyl group in aniracetam?
The anisoyl group is a 4-methoxybenzoyl substituent attached to the nitrogen of a 2-pyrrolidinone ring. It gives aniracetam the IUPAC name 1-(4-methoxybenzoyl)pyrrolidin-2-one, molecular formula C12H13NO3 and molecular weight 219.24 g/mol according to PubChem. It replaces the acetamide side chain that piracetam carries on the same nitrogen.
How does aniracetam differ from piracetam structurally?
Both molecules share the 2-oxopyrrolidine ring, but piracetam carries a primary acetamide on the ring nitrogen and has two nitrogen atoms, while aniracetam carries an aroyl group and has one. Piracetam’s ring nitrogen sits in a tertiary amide; aniracetam’s sits in an imide, flanked by two carbonyls and therefore more reactive towards hydrolysis.
Why is aniracetam more lipophilic than piracetam?
PubChem’s computed XLogP3 value is -1.3 for piracetam and 1.6 for aniracetam, a difference of about 2.9 log units. Acylation adds an aromatic ring and a methoxy group while removing the primary amide and its two hydrogen-bond donors. The result is far stronger retention on reversed-phase columns and much easier extraction into organic solvents.
Why do published assays measure N-anisoyl-GABA rather than aniracetam?
Because the ring-opened metabolite is present in plasma at concentrations that can be quantified reliably. Guenzi and Zanetti developed HPLC methods for both species in 1990, and Cai and Wang published an LC-ESI-MS/MS method in 2012 dedicated to the metabolite, described there as 4-p-anisamidobutyric acid, with a linear range of 0.0485 to 19.4 micrograms per millilitre.
References
- PubChem, Piracetam, CID 4843, National Library of Medicine
- PubChem, Aniracetam, CID 2196, National Library of Medicine
- Ito I. et al., Allosteric potentiation of quisqualate receptors by a nootropic drug aniracetam, Journal of Physiology, 1990
- Isaacson J.S., Nicoll R.A., Aniracetam reduces glutamate receptor desensitization and slows the decay of fast excitatory synaptic currents in the hippocampus, PNAS, 1991
- Guenzi A., Zanetti M., Determination of aniracetam and its main metabolite N-anisoyl-GABA in human plasma by HPLC, Journal of Chromatography, 1990
- Cai S., Wang L., Determination of aniracetam’s main metabolite N-anisoyl-GABA in human plasma by LC-MS/MS, Journal of Chromatography B, 2012
- Tian Y. et al., Pharmacokinetics and bioequivalence study of aniracetam after single-dose administration in healthy Chinese male volunteers, Arzneimittelforschung, 2008
- Malykh A.G., Sadaie M.R., Piracetam and piracetam-like drugs, Drugs, 2010
Research use only. Nonsensia supplies analytical reference standards for laboratory and research applications. This article is published for scientific and educational purposes. It is not medical advice, it does not describe any use in humans, and nothing in it should be read as a recommendation to administer any substance to a person or animal.
Filed under: Chemistry & Discovery
This article is part of our guide to Where Research Compounds Come From: Discovery, Synthesis and Structure.
The compound discussed in this article is available as an analytical reference standard: Aniracetam ≥99% – Analytical Reference Standard | CAS 72432-10-1.